Furthermore, even though a preclinical stroke study could show an increase of MAP2 in the serum of animal subjected to ischemia [43], the conceivable use of MAP2 as a biomarker in the clinical setting has not yet been addressed. The gene discussed is MAP2; the disease is ischemia.